Member Info for Noise

Stumbler, I'm not actually sure Valirx have finished the current 1/2a trial yet.

The last RNS technically did not say the trial had completed, it merely said the trial was "coming to a conclusion", so I think there will be a couple of weeks until it formally closes and they 'freeze' the data for analysis and reporting.

My gut feeling is that there has already been a decision made, either to dump it, or hand it over to a known partner for the 2b/3 heavy lifting trial, for some time now. Administration is not out of the question - so I think we should prepare ourselves for all eventualities. For example, I really don't think we have the resources to progress 301/101 into the next phases, with VAL financing, without some moderately significant event..?

Christ, we could even be reversed into another company, which I think was how Valirx originally came into the world.

I looked it up and it says

"Tuesday 31 December 2019: Markets closing process commences from 12:30 London time. Standard settlement day".

The brokers will shortly be filling the pubs of Weybridge.

This time tomorrow Rodney we'll be BEEEEELLIONAIRES.

Or not.

Yawn, bit bored at the mo.

For the love of God, please no more Hardman reports repeating the same nonsense, RNS' are fine and beyond adequate.
They were great 1-2 times. But let's not waste cash on PR today. If the drugs work, they work. No amount of clever marketing will change that reality.

Apparently it was August 2019.

PS can anyone remind how long ago it was that Suzy took a work break to have her lil bundle of joy?

I'm trying to decide if/when she can realistically come back to full time work.

Yes it's difficult to see which way the co is likely to go.

Can Satu be bothered to continue with 201 the way things are running? Does she want the science and glory, at whatever cost to her investors? (a tricky call).

What's the MCAP now? £1-2m? I would appreciate it if someone just ran away with 401 for £20m.....!

There was a brief period when several posters accused me of being Tarquin... that was quite amusing.

Blurgh, typo, I meant "2b/3 prostate" in my last post.

Drac; Academically yes, financially less so on recent trends ;)

There are a couple of conferences known to be popular with the VAL BoD, perhaps the AACR or TAT in March 2020. I note the abstract cut-off for TAT is in 3 weeks....

I'd like to see something before then, as an early Christmas present (or in silly season, a retirement present!).

This dataset triggers so many other value inflection points, whether they be opening 2a/3 prostate, 2a in breast/ovarian/endo etc. Need to be put out of our financial misery.

Yes, they've had long enough to court partners now, so they might even have a surprise in the background.

I mean, pending results, this could be a good RNS

"...the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA - evidence that is supported from tumour imaging (MRI and CT) in subjects".

Visible on MRI/CT would indicate a moderate size reduction, or at least the avoidance of growth.

Seems... Positive.

Noise wants detail and is hopeful this is the start of better things.

Obelix, a small colony of arachnid-based lifeforms on Mars have signed an LOI.

FACT.

/s

Plus its a nice patent, if it works

"The invention claimed is:
1. A method of preventing the symptoms of a metastatic cancer from worsening, reducing the progression of a metastatic cancer or treating a metastatic cancer in a mammalian subject who is fertile and in whom fertility is to be preserved, the method comprising administering to the subject a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen receptor (AR) or estradiol receptor (ER) in an amount sufficient for preventing the symptoms of the metastatic cancer from worsening, reducing the progression of the metastatic cancer, or treating the metastatic cancer in the subject, wherein the metastatic cancer is one in which an interaction between a Src family kinase and an AR and/or ER is a contributory factor,
2. The method of claim 1, wherein the subject is a human being.
3. The method of claim 2, wherein the molecule is one that binds to the SH3 domain of a Src family kinase.
4. The method of claim 3, wherein the Src family kinase is any of Src, Yes, Fyn, Fgr, Lck, Hck, Blk, Lyn and Frk.
5. The method of claim 1, wherein the peptide has the structure Ac-Pro-Pro-Pro-His-Pro-H is-Ala-Arg-Ile-Lys-NH.sub.2 (SEQ ID NO. 21), where Ac is an acetyl group.
6. The method of claim 5, wherein the metastatic cancer is selected from the group consisting of metastatic fibrosarcoma; metastatic prostate cancer; metastatic breast cancer; metastatic uterine fibroids; metastatic fibroids polyps hyperplasia; metastatic ovarian cancer; metastatic bladder cancer; metastatic cervical cancer; metastatic uterine cancer; metastatic testicular cancer; metastatic lung cancer; metastatic intestinal cancer; metastatic liver cancer; metastatic kidney cancer; and metastatic oesophageal cancer.
7. The method of claim 5, wherein the metastatic cancer is prostate cancer.
8. A method of preventing the symptoms of metastatic prostate cancer from worsening, reducing the progression of metastatic prostate cancer or treating metastatic prostate cancer in a human being who is fertile and in whom fertility is to be preserved,"

Obvs, it has to be proven to work, so there's a moderate amount of work to be done there.

What do you expect from Roses? He literally has one LSE account dedicated to spamming the VAL board, he'll be here moaning until he meets his business objective.

Biopharma is nothing without patents, lets not forget this, the right patent is worth millions (or even crazier amounts).

So far we have been primarily in the 'safety and tolerability' stage of the trial, is this the first indication that we have proven the S&T stage? So we are effectively in the 2a/2b stage?

Christ I hope there is a decent data presentation coming in late 2019....

So... Phase 1 complete, efficacy studies are gogo?

What....mining shenanigans!

Had some good old rises on ATYM back in the day.

Bizarre market behaviour.

Now lets get on with making some bloody lithium :)

Freddie, there's a lot of 'non-protected portfolio', 'single protected transactions' going through, the majority of today's trades so far.

That's usually caused by market makers buying a variety of shares, occasionally when trying to mask the overall quantity of shares on order. Possibly even when a buyer is taking delivery of Valirx shares, as negotiated and recently RNS'd to the market.

Even I don't think "Suzy is working hard to secure a deal" translates to "Glaxo offered $3bn" ;)

I work very hard to convince my boss I should get a £1mpa salary, but so far he's resisted..